News & stories Ovarian cancer news Trial for the drug CT900 which targets ovarian cancer cells expanded into a larger trial A trial for the drug CT900 (previously called ONX-0801) which targets ovarian cancer cells via a protein called the alpha-folate receptor is being expanded into a larger trial. The drug could be suitable for women with ovarian cancer for whom chemotherapy has failed, and whose tumours have high levels of the alpha-folate receptor on the surface of cancer cells. . Read full article